Gunjan L. Shah

Hematology | Oncology

530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 224 publications

Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

Journal: Science translational medicine

Published: July 29, 2026

Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.

Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.

Journal: Blood cancer journal

Published: June 18, 2026

Refractory Mucocutaneous Infections by Herpes Simplex Virus (HSV) in Hematopoietic Cell Transplant Recipients: A Real-world, Multicenter Study.

Refractory Mucocutaneous Infections by Herpes Simplex Virus (HSV) in Hematopoietic Cell Transplant Recipients: A Real-world, Multicenter Study.

Journal: Open forum infectious diseases

Published: May 21, 2026

Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas.

Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas.

Journal: Transplantation and cellular therapy

Published: April 24, 2026

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: March 13, 2026

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Journal: Transplantation and cellular therapy

Published: March 04, 2026

Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignancies.

Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignancies.

Journal: Transplantation and cellular therapy

Published: March 04, 2026

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 23, 2026

A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma.

A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma.

Journal: Haematologica

Published: February 05, 2026

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: February 02, 2026

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: February 02, 2026

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 30, 2026

Showing 1-12 of 224

Last Updated: 09/26/2026